Another Divestment By Takeda, To China’s Hasten For $322m
Executive Summary
Japanese major sheds further non-core assets as it continues to focus on innovation and pay down debt following the Shire acquisition.
You may also be interested in...
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Novartis Xiidra Buy Looks Even Pricier With File Pulled In EU
A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a ground-breaking approval for Alzheimer’s in the US; LAG-3 inhibitors and new Keytruda data generate excitement at ASCO; and clinical progress for another COVID-19 vaccine.